Literature DB >> 20021568

Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale.

Sonja I van Nes1, Els K Vanhoutte, Catharina G Faber, Marcel Garssen, Pieter A van Doorn, Ingemar S J Merkies.   

Abstract

Fatigue is a major disabling complaint in patients with immune-mediated neuropathies (IN). The 9-item fatigue severity scale (FSS) has been used to assess fatigue in these conditions, despite having limitations due to its classic ordinal construct. The aim was to improve fatigue assessment in IN through evaluation of the FSS using a modern clinimetric approach [Rasch unidimensional measurement model (RUMM2020)]. Included were 192 stable patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUSP). The obtained FSS data were exposed to RUMM2020 model to investigate whether this scale would meet its expectations. Also, reliability and validity studies were performed. The original FSS did not meet the Rasch model expectations, primarily based on two misfitting items, one of these also showing bias towards the factor 'walking independent.' After removing these two items and collapsing the original 7-point Likert options to 4-point response categories for the remaining items, we succeeded in constructing a 7-item Rasch-built scale that fulfilled all requirements of unidimensionality, linearity, and rating scale model. Good reliability and validity were also obtained for the modified FSS scale. In conclusion, a 7-item linearly weighted Rasch-built modified FSS is presented for more proper assessment of fatigue in future studies in patients with immune-mediated neuropathies.

Entities:  

Mesh:

Year:  2009        PMID: 20021568     DOI: 10.1111/j.1529-8027.2009.00238.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  11 in total

Review 1.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

2.  Psychometric evaluation of the Fatigue Severity Scale in patients with major depression.

Authors:  Panagiotis Ferentinos; Vassilis Kontaxakis; Beata Havaki-Kontaxaki; Dimitris Dikeos; Lefteris Lykouras
Journal:  Qual Life Res       Date:  2010-10-16       Impact factor: 4.147

3.  Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.

Authors:  Jeffrey A Allen; Mamatha Pasnoor; Mazen M Dimachkie; Senda Ajroud-Driss; Thomas H Brannagan; Albert A Cook; Timothy Walton; Mark B Fiecas; John T Kissel; Ingemar Merkies; Kenneth C Gorson; Richard A Lewis
Journal:  Neurology       Date:  2021-02-16       Impact factor: 9.910

4.  Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathy.

Authors:  Claire M White; Robert D Hadden; Sarah F Robert-Lewis; Paul R McCrone; Jane L Petty
Journal:  BMC Neurol       Date:  2015-08-21       Impact factor: 2.474

5.  Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).

Authors:  S R M Bus; L Zambreanu; A Abbas; Y A Rajabally; R D M Hadden; R J de Haan; C A J M de Borgie; M P Lunn; I N van Schaik; F Eftimov
Journal:  Trials       Date:  2021-02-19       Impact factor: 2.279

Review 6.  Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects.

Authors:  Nowshin Papri; Zhahirul Islam; Sonja E Leonhard; Quazi D Mohammad; Hubert P Endtz; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2021-03-01       Impact factor: 42.937

7.  Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies.

Authors:  Yuri M Falzone; Marta Campagnolo; Mariangela Bianco; Patrizia Dacci; Daniele Martinelli; Marta Ruiz; Silvia Bocci; Federica Cerri; Angelo Quattrini; Giancarlo Comi; Luana Benedetti; Fabio Giannini; Giuseppe Lauria; Eduardo Nobile-Orazio; Chiara Briani; Raffaella Fazio; Nilo Riva
Journal:  J Neurol       Date:  2018-10-10       Impact factor: 4.849

8.  Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  K Kuitwaard; E Brusse; B C Jacobs; A F J E Vrancken; F Eftimov; N C Notermans; A J van der Kooi; W-J R Fokkink; D Nieboer; H F Lingsma; I S J Merkies; P A van Doorn
Journal:  Eur J Neurol       Date:  2020-10-01       Impact factor: 6.089

9.  Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

Authors:  S R M Bus; M C Broers; F Eftimov; I M Lucke; C Bunschoten; G G A van Lieverloo; M E Adrichem; R van Veen; L Wieske; H F Lingsma; H S Goedee; W L van der Pol; I N van Schaik; P A Van Doorn; B C Jacobs
Journal:  J Neurol       Date:  2021-06-26       Impact factor: 6.682

10.  Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.

Authors:  Christine Verboon; Thomas Harbo; David R Cornblath; Richard A C Hughes; Pieter A van Doorn; Michael P Lunn; Kenneth C Gorson; Fabio Barroso; Satoshi Kuwabara; Giuliana Galassi; Helmar C Lehmann; Susumu Kusunoki; Ricardo C Reisin; Davide Binda; Guido Cavaletti; Bart C Jacobs
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-06-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.